Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	4.25	3.25	26.48	41.71	70.07
Cash & Short-Term Investments	4.25	3.25	26.48	41.71	70.07
Cash Growth	30.76%	-87.72%	-36.51%	-40.47%	405.59%
Inventory	22.29	8.27	-	-	-
Prepaid Expenses	1.4	2.7	7.89	2.85	2.74
Total Current Assets	27.93	14.22	34.37	44.56	72.81
Property, Plant & Equipment	0.82	0.25	0.46	0.65	0.83
Goodwill	9.35	9.35	9.35	9.35	9.35
Other Intangible Assets	92.8	92.8	59.4	59.4	59.4
Other Long-Term Assets	0.04	0.04	0.04	0.04	0.04
Total Assets	130.94	116.65	103.61	114	142.43
Accounts Payable	13.69	4.93	2.93	1.17	1.28
Accrued Expenses	7.48	2.25	2.63	3.17	2.53
Short-Term Debt	1	-	-	-	-
Current Portion of Leases	0.09	0.24	0.22	0.2	0.18
Other Current Liabilities	22.65	28.4	-	-	-
Total Current Liabilities	44.91	35.81	5.78	4.53	3.98
Long-Term Leases	0.72	0.02	0.26	0.48	0.68
Long-Term Deferred Tax Liabilities	7.77	6.71	6.14	5.56	4.99
Total Liabilities	53.41	42.55	12.18	10.57	9.65
Common Stock	0.02	0.01	0.01	0.15	0.15
Additional Paid-In Capital	306.34	271.44	253.06	232.37	228.08
Retained Earnings	-238.8	-201.37	-162.23	-129.69	-96.05
Total Common Equity	67.55	70.08	90.83	102.83	132.18
Minority Interest	9.98	4.02	0.6	0.6	0.6
Shareholders' Equity	77.53	74.1	91.43	103.43	132.78
Total Liabilities & Equity	130.94	116.65	103.61	114	142.43
Total Debt	1.81	0.26	0.48	0.68	0.86
Net Cash (Debt)	2.44	2.99	26	41.03	69.22
Net Cash Growth	-18.40%	-88.50%	-36.64%	-40.72%	453.40%
Net Cash Per Share	0.22	0.44	4.30	7.02	15.93
Filing Date Shares Outstanding	20.76	7.73	6.36	5.85	5.84
Total Common Shares Outstanding	18.07	7.25	6.35	5.85	5.84
Working Capital	-16.98	-21.59	28.59	40.03	68.83
Book Value Per Share	3.74	9.67	14.29	17.58	22.64
Tangible Book Value	-34.6	-32.07	22.08	34.08	63.44
Tangible Book Value Per Share	-1.91	-4.43	3.48	5.83	10.86

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q